Treats neuropathic pain associated with postherpetic neuralgia (PHN). Sold as Qutenza. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Capsaicin (sold as Qutenza), first approved Nov 16, 2009, with 1 new use approved and 0 published complete response letters.
| Effects of a Preoperative Capsaicin-Containing Diet on Postoperative Liver Injury RepairPostoperative Liver Injury · Tongji Hospital | Not applicable | Not yet recruiting | Nov 9, 2026 |
| High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral NeuropathyChemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy · Case Comprehensive Cancer Center | Phase 4 | Not yet recruiting | Sep 22, 2026 |
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPainful Diabetic Neuropathy (PDN), Diabetic Nephropathies · University of Michigan | Phase 4 | Not yet recruiting | Aug 31, 2026 |
| Marsili Syndrome as a Gateway to Novel Analgesic TargetsMarsili Syndrome · Aalborg University | Not applicable | Active, not recruiting | Aug 10, 2026 |
| TaVNS for Capsaicin-Induced PainPain Management, Capsaicin-Induced Pain · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Not yet recruiting | Jul 22, 2026 |
| Pain Beliefs and Intracortical Excitability During Experimental PainKinesiophobia (Fear of Movement), Experimental Pain · Université de Sherbrooke | Not applicable | Not yet recruiting | Jul 7, 2026 |
| Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin PatchesNeuropathic Pain, Nociplastic Pain · Nantes University Hospital | Not applicable | Not yet recruiting | Jun 22, 2026 |
| Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase ⅠHealthy Participants Study · First Affiliated Hospital of Zhejiang University | Phase 1 | Recruiting | Jun 10, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
